Skip to search formSkip to main contentSkip to account menu

Eplivanserin Hemifumarate

Known as: (4-((1E,3Z)-3-((2-(Dimethylamino)Ethoxy)Imino)-3-(2-Fluorophenyl)Prop-1- Enyl)Phenol)(2E)-2-Butenedioate (2:1), 2-Propen-1-One, 1-(2-Fluorophenyl)-3-(4-Hydroxyphenyl)-, O-(2- (Dimethylamino)Ethyl)Oxime, (1z,2e)-, (2e)-2-Butenedioate (2:1), SR46349B 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The serotonergic system appears crucial for (±)-3,4-methylenedioxymethamphetamine (MDMA) reinforcing properties. Current evidence… 
2011
2011
RationaleAtypical antipsychotic efficacy is often attributed to actions at serotonin-2 (5-HT2) and dopamine receptors, indicating… 
2009
2009
Although nicotine is generally considered to be the main compound responsible for addictive properties of tobacco, experimental… 
2007
2007
RationaleAlthough locomotor response to d-amphetamine is considered as mediated by an increased release of dopamine in the… 
2007
2007
Strategies for the use of germanium-based linkers for the phase-tagged synthesis of isotopically labelled intermediates are… 
Highly Cited
2006
Highly Cited
2006
In rodents, drugs of abuse induce locomotor hyperactivity, and repeating injections enhances this response. This effect, called… 
2005
2005
RationaleClozapine inhibits sympathetic outflow to the cutaneous vascular bed. Clozapine reverses hyperthermia and cutaneous… 
2004
2004
D-amphetamine is known to induce an increase in dopamine release in subcortical structures, thus inducing locomotor hyperactivity… 
2002
2002
The intrastriatal injection of 6‐hydroxydopamine (6‐OHDA) in newborn rats produces a marked striatal dopamine (DA) depletion…